Growth Metrics

Conmed (CNMD) Equity Average (2016 - 2026)

Conmed filings provide 16 years of Equity Average readings, the most recent being $1.0 billion for Q1 2026.

  • On a quarterly basis, Equity Average rose 5.69% to $1.0 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $1.0 billion, a 5.69% increase, with the full-year FY2025 number at $997.9 million, up 11.07% from a year prior.
  • Equity Average hit $1.0 billion in Q1 2026 for Conmed, roughly flat from $1.0 billion in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $1.0 billion in Q1 2026 to a low of $694.7 million in Q3 2022.
  • Median Equity Average over the past 5 years was $844.4 million (2024), compared with a mean of $861.4 million.
  • Biggest five-year swings in Equity Average: decreased 7.39% in 2022 and later grew 16.26% in 2024.
  • Conmed's Equity Average stood at $730.9 million in 2022, then increased by 11.53% to $815.2 million in 2023, then rose by 16.26% to $947.8 million in 2024, then grew by 7.69% to $1.0 billion in 2025, then rose by 0.46% to $1.0 billion in 2026.
  • The last three reported values for Equity Average were $1.0 billion (Q1 2026), $1.0 billion (Q4 2025), and $1.0 billion (Q3 2025) per Business Quant data.